ResProt JMIR Res Protoc JMIR Research Protocols 1929-0748 JMIR Publications Toronto, Canada v15i1e77429 42302269 10.2196/77429 Protocol Protocol Prevalence of and Risk Factors for Metabolic Syndrome, Vascular Damage, and Accelerated Aging (MetVasA) After Pediatric Hematopoietic Stem Cell Transplantation for Hematological Malignancy: Protocol for a Cross-Sectional Cohort Study Sarvestan Javad Egger-Heidrich Katharina Otth Maria Asbroek Lisa J MD 1 https://orcid.org/0009-0008-1295-2945 van der Pal Helena JH MD, PhD 1 https://orcid.org/0000-0003-2253-2115 Fiocco Marta PhD 1 2 3 https://orcid.org/0000-0001-5588-0277 Feijen Elizabeth AM PhD 1 https://orcid.org/0000-0001-8930-3160 Grundeken Lucienne H MSc 4 https://orcid.org/0009-0009-8935-3585 Koopman Maria MW MD, PhD 1 https://orcid.org/0009-0002-9451-4098 van Litsenburg Raphaële RL MD, PhD 1 https://orcid.org/0000-0003-1779-6159 van der Torre Patrick MSc 1 https://orcid.org/0000-0001-9697-2418 Westerink Jan MD, PhD 5 https://orcid.org/0000-0001-5021-5227 Kremer Leontien CM MD, PhD 1 6 https://orcid.org/0000-0001-7422-3248 Pluijm Saskia MF PhD 1 https://orcid.org/0000-0002-4459-7799 Bresters Dorine MD, PhD 1
Princess Máxima Center for Pediatric Oncology Heidelberglaan 25 Utrecht, 3584 CS The Netherlands 31 650006515 ext 29515 D.Bresters@prinsesmaximacentrum.nl
https://orcid.org/0000-0002-5417-4159 Princess Máxima Center for Pediatric Oncology Utrecht The Netherlands Mathematical Institute Leiden University Leiden The Netherlands Department of Biomedical Data Sciences Leiden University Medical Center Leiden The Netherlands Trial and Data Center Princess Máxima Center for Pediatric Oncology Utrecht The Netherlands Department of Internal Medicine Isala Hospital Zwolle The Netherlands Wilhemina Children's Hospital University Medical Center Utrecht Utrecht The Netherlands Corresponding Author: Dorine Bresters D.Bresters@prinsesmaximacentrum.nl 2026 16 6 2026 15 e77429 15 5 2025 10 7 2025 12 12 2025 ©Lisa J Asbroek, Helena JH van der Pal, Marta Fiocco, Elizabeth AM Feijen, Lucienne H Grundeken, Maria MW Koopman, Raphaële RL van Litsenburg, Patrick van der Torre, Jan Westerink, Leontien CM Kremer, Saskia MF Pluijm, Dorine Bresters. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 16.06.2026. 2026

This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on https://www.researchprotocols.org, as well as this copyright and license information must be included.

 Background

Survivors of hematopoietic stem cell transplantation (HSCT) in childhood face a high risk of metabolic and cardiovascular disease as well as accelerated aging. Estimates of the prevalence of these severe late effects have varied widely because they have been based on small cohorts or mixed populations of patients that received transplantations for both malignant and nonmalignant diseases, and the co-occurrence of these late effects was not assessed. Therefore, the true burden of these complications in survivors of hematological malignancies remains unclear. Moreover, the role of potentially modifiable risk factors such as health behaviors and inflammation has not yet been determined.

 Objective

This study aims to determine the prevalence of metabolic syndrome (MetS), endothelial dysfunction (ED), and accelerated aging and their risk factors, including treatment-related factors, inflammation, and health behaviors, in a large representative cohort of Dutch survivors of HSCT in childhood. Additionally, the study will examine the co-occurrence of these late effects.

 Methods

This cross-sectional cohort study will combine 2 cohorts of survivors of HSCT in childhood for a hematological malignancy. The first cohort (cohort 1; n=102) consists of survivors who received transplantations before 2002 and were participants of the Dutch Childhood Cancer Survivor Study LATER 2 cohort, a nationwide cohort study focusing on late effects among long-term childhood cancer survivors. The second cohort will include survivors who received transplantations between 2002 and 2021 (cohort 2; projected n=120) and visited the late effects (LATER) outpatient clinic of the Princess Máxima Center between 2024 and 2026. Key outcomes will be the prevalence of MetS (≥3 of 5 clinical criteria), accelerated aging (3 of 5 biological and clinical criteria), and ED (assessed by endothelial peripheral arterial tonometry) and their co-occurrence. A broad range of potential and modifiable risk factors will be investigated, including treatment-related factors; transplant complications (eg, graft-versus-host disease); and health behaviors, including physical activity, dietary intake and status assessed with nutritional biomarkers, substance use, sun exposure, and relaxation.

 Results

Patient recruitment started in January 2024 and is estimated to last until June 2026. As of September 2025, a total of 77 participants have been included in the study.

 Conclusions

This study will provide insight into the prevalence of MetS, ED, and accelerated aging, as well as potentially modifiable risk factors, including those that have not been previously examined, among survivors of HSCT for hematological malignancies in childhood. The findings will inform surveillance guidelines and support the development of health behavioral and anti-inflammatory interventions to mitigate the risk of these severe late effects.

 International Registered Report Identifier (IRRID)

DERR1-10.2196/77429

 metabolic syndrome endothelial dysfunction vascular damage accelerated aging health behaviors survivors of childhood cancer hematopoietic (stem) cell transplantation late effects pediatric oncology Introduction

Allogeneic hematopoietic stem cell transplantation (HSCT) offers a potentially curative treatment for some children with a hematological malignancy and has been increasingly used over the past decades [1]. Advances in stem cell availability, treatment modalities, and supportive care have significantly improved survival rates after HSCT [2]. However, HSCT remains an intensive treatment with a substantial burden of late effects. Survivors of HSCT face a higher risk of severe late effects as compared to patients treated with chemotherapy alone, which may negatively impact their quality of life [3]. Metabolic syndrome (MetS) and vascular disease are among the most frequently observed late effects [3-12].

Survivors of HSCT have a high risk of developing MetS or its components, including overweight, insulin resistance, and diabetes mellitus [13-24]. The estimated prevalence of MetS in survivors of HSCT ranges from 23% to 49%, whereas in the general Dutch population aged 30 to 40 years and 40 to 50 years, the prevalence is 14% and 24%, respectively [25]. MetS is strongly associated with a high risk of developing diabetes mellitus and cardiovascular disease (CVD) [26].

CVD is another frequent and potentially severe late effect in survivors of HSCT, with cumulative incidences ranging from 4% to 48% after a median follow-up of 3 to 25 years [21,27-31]. Endothelial dysfunction (ED) can be an early sign of CVD and thus predicts an increased risk for cardiovascular morbidity [32,33].

In addition to vascular and metabolic complications, survivors of HSCT often experience multiple other aging-related morbidities in young or middle-age adulthood that are typically seen in the older general population. Frailty, an aging phenotype primarily described in older adults, is over 4 times more prevalent in survivors of HSCT than in survivors treated with chemotherapy alone [34]. This indicates that a process of accelerated aging occurs, which has also been suggested by other studies in survivors of HSCT [3,6,35-38]. This phenomenon impairs quality of life and predisposes survivors of HSCT to early morbidity and mortality.

Vascular and metabolic diseases are linked through shared pathophysiologic pathways [39]. Similarly, graft-versus-host disease (GvHD) and ED syndromes share a common pathophysiology that is characterized by tissue damage, cytokine release, and inflammation with endothelial injury [40-43]. HSCT is characterized by severe tissue damage caused by the conditioning regimen, along with severe immunosuppression in the initial phase, which is often complicated by infectious problems. Together, these factors lead to an inflammatory milieu. Engraftment and immune reconstitution may trigger immune dysregulation and inflammation, potentially leading to acute GvHD and further amplifying this inflammatory state [44-49]. Chronic GvHD and its treatment are also identified as important risk factors for the development of late effects and may contribute to long-term inflammation [7,9,10,50,51]. The conditioning regimen, immune dysregulation, inflammation, GvHD and its treatment, as well as infection or viral reactivation may contribute to endothelial damage. Moreover, posttransplant ED syndromes are characterized by endothelial activation and damage [40-42]. MetS, ED, and aging may also be linked to several predisposing unhealthy lifestyle behaviors such as sedentary behavior, low levels of physical activity, and unbalanced dietary patterns [52-56]. The co-occurrence of MetS, ED, and other aging-related hallmarks predispose survivors of HSCT to CVD, disability, impaired quality of life, and early mortality (Figure 1).

Potential risk factors for and consequences of metabolic syndrome, endothelial dysfunction, and accelerated aging. HSCT: hematopoietic stem cell transplantation.

Up until now, studies investigating late effects in childhood survivors of HSCT have been limited by small sample sizes and heterogeneous populations, often including survivors who received transplantations for malignant diseases as well as those whose transplantations were for nonmalignant disease. Thus, the estimates of the prevalence of these late effects have been imprecise and not specific to survivors of hematological malignancies. There is a need to better understand these late effects and their associated risk factors.

Late effects after HSCT likely result from a combination of risk factors related to the treatment and transplant, lifestyle behavior, and sociodemographics [7,9,10,50,51,57]. Although previous studies examined the conditioning regimen and total body irradiation as risk factors for developing MetS or vascular disease in survivors of HSCT, lifestyle behaviors or HSCT-related complications (eg, chronic GvHD and ED syndromes) have not been examined so far [14,26,58]. Identifying (potentially modifiable) risk factors, including lifestyle behaviors, may aid in developing targeted prevention strategies for those with the highest risk of developing these late effects [35,59,60].

The Metabolic Syndrome, Vascular Damage, and Accelerated Aging (MetVasA) study aims to provide a comprehensive analysis of MetS, ED (as an early sign of vascular disease), and accelerated aging in a nationwide cohort of survivors of HSCT for a hematological malignancy in childhood. The primary aims of this study are to determine the prevalence of and risk factors for (1) MetS, (2) ED, and (3) accelerated aging. Transplant-related factors (eg, conditioning regimen, donor type, and stem cell source), transplant-related complications (eg, ED syndromes and GvHD), sociodemographic factors, and lifestyle behaviors will be examined. Second, we will determine the (4) coexistence of MetS, ED, and accelerated aging and their combined risk factors, and (5) prevalence of unhealthy lifestyle behaviors, including smoking, excessive alcohol consumption, other substance use, low level of physical activity, poor quality and/or quantity of sleep, and poor dietary intake of vitamins and nutrients.

 Methods Study Design and Population Overview

The MetVasA study is a cross-sectional study comprising 2 cohorts of long-term survivors of HSCT who underwent HSCT for a hematological malignancy during childhood. Data of the first cohort were previously collected as part of the Dutch Childhood Cancer Survivor Study (DCCSS) LATER 2 study (cohort 1). A second cohort, consisting of more recently treated survivors of HSCT, will be invited for this study at the late effects (LATER) outpatient clinic of the Princess Máxima Center for Pediatric Oncology in Utrecht, the Netherlands (cohort 2). To enhance statistical power, data from both cohorts will be pooled (Figure 2).

Overview of cohorts for the Metabolic Syndrome, Vascular Damage, and Accelerated Aging study. DCCSS-LATER: Dutch Childhood Cancer Survivor Study-LATER; HSCT: hematopoietic stem cell transplantation.

 Cohort 1: DCCSS-LATER 2 Study Participants

The DCCSS-LATER study cohort is a national cohort of childhood survivors of cancer and includes >6000 survivors diagnosed between January 1, 1963, and December 31, 2001, before the age of 18 years, who survived at least 5 years after diagnosis and were treated in 1 of the 7 pediatric oncology centers in the Netherlands. The DCCSS-LATER study comprises 2 parts. Part 1 consists of a general health and health behavior questionnaire. Part 2 (from 2016 to 2020) includes the evaluation of a broad spectrum of late effects and possible risk factors using diagnostic methods such as blood samples, imaging studies, and organ function assessments. The methodology of this study has been described in more detail previously [61]. A representative sample of 102 survivors of HSCT participated in the DCCSS-LATER 2 study and the DCCSS-LATER 2 substudies on MetS and aging.

 Cohort 2: Survivors of HSCT From 2002 to 2021

A second, newly established cohort will include both adult survivors as well as survivors aged <18 years, who underwent HSCT in childhood (aged ≤18 years at the time of HSCT) for a hematological malignancy between January 1, 2002, and January 1, 2021. Eligible survivors must be alive for at least 2 years after transplant and currently receiving follow-up care at the LATER outpatient clinic of the Princess Máxima Center for Pediatric Oncology. Participants must be at least 4 years old at the time of inclusion in this study to ensure they can comply with study procedures. This cohort consists of approximately 255 survivors, of which we aim to include 120 survivors based on the power calculation (refer to the Power calculation section). Exclusion criteria include active treatment for a relapse or secondary malignancy, (possible) pregnancy, and insufficient proficiency in Dutch language or illiteracy.

Every month, the coordinating researcher will receive a list of eligible participants scheduled for routine follow-up appointments at the late effects outpatient clinic of the Princess Máxima Center for Pediatric Oncology in the upcoming months. The coordinating researcher contacts the eligible participants before their regular scheduled follow-up visit to inform them about the study and invite them to participate. If they agree to participate, written informed consent will be obtained.

To assess the representativeness of the final study sample, aggregated data on the total eligible cohort will be obtained from the Dutch Childhood Cancer Survivor Registry (DCCSR).

 Data Collection

Data and samples of cohort 1 were previously collected in the DCCSR. For participants in cohort 2, a study visit will be scheduled to coincide with their regular follow-up care visit to the LATER outpatient clinic in the Princess Máxima Center to minimize participant burden. During this study visit, a venous blood sample will be collected simultaneously with the blood draw performed for their regular follow-up care. Furthermore, anthropometric measurements and several clinical tests will be performed, as discussed in Assessment of Outcomes. In addition to the study visit, participants will be asked to complete online questionnaires. For participants aged <12 years, the legal guardian will be requested to complete the questionnaires together with the participant. Furthermore, all participants will be asked to complete a home-based measurement week within 3 months after their study visit, as discussed in Assessment of Health Behaviors.

Detailed information on the type of hematological malignancy and treatment for the primary disease and any recurrences will be retrieved from the DCCSR. Data on HSCT characteristics (eg, condition regimen, donor type, and stem cell source) and post-HSCT complications (eg, ED syndromes and GvHD) will be extracted from medical records.

 Assessment of Outcomes Assessment of MetS and Its Components

We will assess MetS and its components in participants of both cohorts using the modified National Cholesterol Education Program Adult Treatment Panel III criteria for participants aged ≥16 years [62]. For children aged <16 years, there is no consensus on the cutoff values for each criterion. On the basis of existing literature, we will use the criteria proposed by Ahrens et al [63] for children aged 4 to 10 years (Identification and Prevention of Dietary- and Lifestyle-Induced Health Effects in Children and Infants criteria) [64]. As the Identification and Prevention of Dietary- and Lifestyle-Induced Health Effects in Children and Infants study provided no reference values for the homeostatic model assessment of insulin resistance, triglycerides, and high-density lipoprotein cholesterol for children aged ≥11 years, , we will use the National Cholesterol Education Program Adult Treatment Panel III pediatric criteria for participants aged 11 to 16 years (Table 1) [65]. Adiposity will be assessed by waist circumference (WC; measured at the middle between the lower rib and iliac crest to the nearest centimeter) and body fat t score or z score (assessed by dual-energy x-ray absorptiometry [DXA]). Insulin resistance will be assessed by fasting glucose and/or with the Homeostatic Model Assessment of Insulin Resistance ([fasting insulin (µU/mL)×fasting glucose (mmol/L)]/22.5). Dyslipidemia will be assessed by levels of triglycerides and high-density lipoprotein cholesterol. Hypertension will be assessed by the mean of 2 blood pressure measurements in a sitting position using an electronic oscillometric meter, with 5 minutes of rest between the 2 measurements. Medical records will be checked for the current use of medication for either diabetes mellitus, hypertension, or dyslipidemia.

Indicators, definitions, and criteria for determination of metabolic syndrome.

NCEP ATP-IIIa adult criteria (2005; aged ≥16 years)b NCEP ATP III pediatric criteria (2005; aged 11-16 years)b IDEFICSc criteria (aged ≤10 years)b Alternative with DXAd-scane
Adiposity
Waist circumference (cm) >102f/88g ≥90th percentile (age- and sex-specific) ≥90th percentile (age- and sex-specific) Body fat t score/z score>2
Insulin resistance
Fasting glucose (mmol/L) ≥5.6 or treatment ≥5.6 or treatment ≥90th percentile or HOMA-IRh ≥90th percentile or treatment —i
Dyslipidemia
Triglycerides (mmol/L) ≥1.7 or treatment ≥1.2 or treatment ≥90th percentile or treatment —
HDLj cholesterol (mmol/L) <1.0f/1.3g or treatment <1.0 or treatment ≤10th percentile or treatment —
Hypertension
Blood pressure (mmHg) ≥130/85 or treatment ≥90th percentile of SBPk or DBPl (age-, sex-, and height-specific) or treatment ≥90th percentile of SBP or DBP (age-, sex-, and height-specific) or treatment —

aNCEP ATP III: National Cholesterol Education Program Adult Treatment Panel III.

b≥3 of the components in each column are required for diagnosis.

cIDEFICS: Identification and Prevention of Dietary- and Lifestyle-Induced Health Effects in Children and Infants.

dDXA: dual-energy x-ray absorptiometry.

eAdiposity assessed by body fat t score/z score was used instead of waist circumference in the diagnosis of metabolic syndrome to explore potential underestimation of adiposity by waist circumference in this cohort.

fMen.

gWomen.

hHOMA-IR: homeostatic model assessment for insulin resistance.

iNot applicable.

jHDL: high-density lipoprotein.

kSBP: systolic blood pressure.

lDBP: diastolic blood pressure.

 Assessment of ED

Endothelial function will be assessed using a standardized procedure with endothelial peripheral arterial tonometry using the EndoPAT2000 (Itamar Medical, Caesarea, Israel) in accordance with the instruction manual [66]. This assessment will only be performed in cohort 2. ED established by endothelial peripheral arterial tonometry has been shown to be a simple and reliable measurement technique to assess endothelial function in adults and adolescents [67-69]. To define an abnormal reactive hyperemia index (RHI) in adults, the validated cutoff point of the RHI of 1.35 will be used. Age-specific normal values of the RHI have not been established for children. Median values that have been reported in other studies for children aged 12 to 18 years are 2.15 for lean children with normal lipid levels and 1.50 for severely obese children. Therefore, for children, we will use an RHI cutoff value of 1.50.

 Assessment of Accelerated Aging and Its Indicators Overview

For assessing accelerated aging, we composed a comprehensive score with five indicators: (1) multimorbidity, (2) inflammation, (3) aberrant body composition, (4) poor muscle strength, and (5) poor physical function. We define accelerated aging as the presence of at least 3 of 5 indicators. Figure 3 shows an overview of the assessment of these indicators.

Aging indicators. BIA: bioimpedance analysis; DXA: dual-energy x-ray absorptiometry.

 Multimorbidity

Multimorbidity will be assessed with a questionnaire and data retrieved from the medical records regarding the presence, type, and number of chronic diseases and medication use. The 18-item Pediatric Quality of Life Inventory 3.0 Multidimensional Fatigue Scale will be used to assess fatigue [70]. Multimorbidity will be defined as the coexistence of ≥2 age-related chronic diseases, including but not limited to fatigue, renal and heart failure, pulmonary and musculoskeletal diseases, diabetes, osteoporosis, and subsequent malignant neoplasms.

 Inflammation

Inflammation will be assessed by analysis of inflammatory biomarkers in blood samples, including high sensitivity C-reactive protein, tumor necrosis factor-α, interleukin-6, and interleukin-10. Inflammation will be defined as the presence of ≥2 elevated inflammatory markers.

 Aberrant Body Composition

Body composition was assessed by DXA and anthropometry in cohort 1. DXA was used to establish the amount of appendicular lean body mass, total fat, bone mass, and bone mineral density. Z scores will be calculated for lean body mass, fat mass, and bone mineral density. Furthermore, BMI (kg/m2), calculated from body weight (kg) measured with a beam scale to the nearest 0.1 kg and body height (cm) assessed with a stadiometer without shoes to the nearest centimeter, and WC, as described for MetS, were assessed. For cohort 2, body composition will be assessed similarly with DXA and anthropometric measurements. However, we will also perform a bioimpedance analysis (Tanita MC700A). Bioimpedance analysis is an inexpensive, accessible, user-friendly, noninvasive, and reliable method in which body composition is assessed by measuring bioelectrical resistance [71]. We will calculate z scores for lean body mass, fat mass, and bone mass. Their agreement with DXA will also be assessed. We will score body composition on low muscle mass, underweight, and adiposity. Low muscle mass will be defined as a lean body mass z score ≤2. Underweight will be defined as fat mass z score ≤2 or a BMI <18.5 for participants aged ≥19 years and BMI <17.0 for participants aged <19 years. Adiposity will be defined as fat mass z score >2 or increased WC using the same cutoff values as for MetS (Table 1). Additionally, the Body Roundness Index will be calculated (364.2 − 365.5 × {1−[(WC / 2π) / (0.5 × height)]}). The Body Roundness Index might be a better predictor for MetS than BMI and WC, as this is a predictor for body fat percentage and visceral adiposity tissue [72].

 Poor Muscle Strength

Muscle strength was or will be assessed in both cohorts by handgrip strength using a handheld dynamometer (Jamar plus). Participants were or will be asked to perform 2 maximum force trials with each hand. The maximum of the right and left hand will be summed and used as the final score. The hand grip strength will be scored as poor with a score <10th% based on reference data.

 Poor Physical Function

In cohort 1, physical functioning was assessed using the 6-minute-walking test (6MWT) [73,74, 75], a submaximal test of aerobic capacity where participants were encouraged to walk as fast as possible for 6 minutes along a 20-m track. The total distance covered in 6 minutes was recorded as the score. Additionally, self-reported physical function was evaluated using the physical function and vitality subscales of the Medical Outcome Study 36-item short form questionnaire [76].

In cohort 2, physical performance will be assessed more comprehensively. As in cohort 1, self-reported physical function will be assessed using the physical function and vitality subscales of the Medical Outcome Study 36-item short form questionnaire. Participants will also be asked to complete the Tilburg Frailty Index [77]. Additionally, several aspects of physical performance will be assessed with test batteries tailored to different age groups.

For participants aged <18 years, physical performance will be assessed using the Eurofit test battery, which includes various health-related and skill-related fitness tests [78]: Flamingo balance test (balance), plate tapping (upper body speed), sit-and-reach (flexibility), standing broad jump (lower body muscular strength), handgrip strength (upper body muscular strength), sit-ups (abdominal muscular endurance), bent arm hang (upper body muscular endurance), 10×5-m agility shuttle run (running speed-agility), and a 20-m shuttle run (cardiorespiratory fitness).

For participants aged ≥18 years, physical performance will be assessed using the Short Physical Performance Battery [74,79], handgrip strength [80], 6MWT, and the steep ramp test (SRT) [81-83]. The 6MWT is described above. The Short Physical Performance Battery includes a timed 4-m walk (gait speed), chair sit-to-stand test (lower body muscular strength), and standing balance tests (total score 0-12). The SRT is performed on a calibrated cycle ergometer on which the work rate (wattage) is linearly increased by a ramp protocol, and participants need to maintain a minimal number of revolutions per minute (60 rpm) up to a maximal achieved wattage. The SRT performance is strongly associated with peak oxygen uptake and provides a reliable indication of cardiorespiratory fitness.

 Assessment of Health Behaviors

The health behaviors of the participants will be assessed with questionnaires and laboratory tests in both cohorts.

In cohort 1, participants completed the Short Questionnaire to Assess Health-Enhancing Physical Activity to assess the level of physical activity [84]. In cohort 2, the Short Questionnaire to Assess Health-Enhancing Physical Activity was also used, but additional assessments were conducted using the Patient-Reported Outcomes Measurement Information System Sleep Disturbance 8-item short form [85,86] and a more comprehensive questionnaire on health behaviors that includes substance use (smoking, alcohol consumption, and drug use), supplement use, dietary intake, meditation, mindfulness, and sun exposure.

In cohort 2, participants will undergo a measurement week using 2 accelerometers (ActiGraph wGT3x-BT) to measure sleep quantity and quality, as well as frequency and intensity of physical activity [87]. Additionally, participants will be requested to keep a diary documenting if the accelerometers were temporarily removed, which physical activity they engaged in, and whether they took a nap during the day. During this measurement week, participants will also track their nutrition for 3 days using the Eetmeter app (Voedingscentrum). Data from the Eetmeter app, combined with the questionnaire on health behaviors, will be analyzed using the Dutch Healthy Diet Index [88,89].

In both cohorts, laboratory tests to assess nutritional status and nutrient levels will be performed.

 Power Calculation

Power calculations were conducted for all outcomes. The sample size is based on the power calculation for MetS, as this is our primary outcome. Assuming the population proportion under the null hypothesis of 20% and under the alternative hypothesis of 28%, calculation performed using G*Power indicated that a sample size of n=222 is needed to detect a difference of 8% between the alternative hypothesis and the null hypothesis using a 2-sided binomial test with 80% power. The target significance is P=.05, and actual significance level achieved is P=.04. We already have a cohort (cohort 1) of 102 survivors, so we will need to include 120 additional survivors in cohort 2. With a total sample size of 222 survivors and an expected prevalence of 0.28 for MetS, the 95% CI for the estimated proportion will be 0.22-0.34.

 Statistical Analysis

SPSS Statistics (version 29.0.0; IBM Corp) will be used for statistical analyses. Categorical data will be summarized as frequencies and percentages. For continuous data, the mean, SD, and median will be presented. Descriptive statistics will be used to compare participants with and without MetS, ED, or accelerated aging. A 2-sided binomial test will be used to compare the prevalence of MetS in the different groups. The prevalence will be estimated within categories of attained age, sex, and follow-up time. Additionally, multivariable regression analysis will be used to adjust the estimated prevalence for the entire cohort, accounting for age at diagnosis, sex, attained age, and/or follow-up time. Estimated prevalences with 95% CI will be presented. Furthermore, a sensitivity analysis will be conducted, in which the prevalence with and without participants with <5 years of follow-up will be compared. Student t test (for normally distributed continuous variables), Mann-Whitney U test (for skewed continuous variables), and χ2 test (for categorical variables) will be used to compare participants and nonparticipants (those who were eligible but did not participate).

To determine the association between potential risk factors (treatment-related factors, HSCT-related factors, sociodemographics, and unhealthy lifestyle behaviors) and MetS, ED, and accelerated aging, univariable and multivariable logistic regression models will be estimated. Odds ratios with 95% CI will be reported.

Univariable and multivariable multinomial models will be estimated to study the association between independent variables and the co-occurrence of MetS, ED, and accelerated aging. The outcome will be categorized as having (1) 1 late effect (either MetS, ED, or accelerated aging), (2) 2 late effects (any combination of MetS, ED, and accelerated aging), and (3) all 3 late effects.

 Ethical Considerations

The MetVasA study was approved by the Central Medical Research Ethics Committee (NedMec) in June 2023 and is registered at the Central Committee on Research Involving Human Subjects (NL83998.041.23). In addition, the study received approval from the local Research Ethics Committee at the Princess Máxima Center for Pediatric Oncology. Participants in cohort 1 have previously provided written informed consent in the context of the DCCSS-LATER 2 study. Permission for secondary analyses without the need for additional consent was included in this initial consent and is covered under the current ethical approval. For all participants in cohort 2, written informed consent will be obtained. Participants receive detailed information about the purpose, procedures, risks, and benefits of the study prior to participation, and are informed about their right to withdraw their informed consent at any time without negative repercussions and the obligation to provide a reason; if a reason is given, it will be documented. To assess feasibility and acceptability, inclusion and dropout rate will be monitored closely. To protect participant confidentiality, all data will be deidentified prior to analysis. Participants do not receive any financial compensation for participation.

 Results

Funding for this study was obtained in October 2022, and the first participant was included in January 2024. As of September 2025, a total of 77 participants have been included in the study and completed the study visit. The recruitment of participants is expected to continue until June 2026. The results of this study are expected to be published between late 2026 and early 2027.

 Discussion

In the MetVasA study, we will assess the prevalence of and risk factors for MetS, ED, and accelerated aging in survivors of HSCT in childhood for a hematological malignancy, as well as the prevalence of an unhealthy lifestyle in these survivors. Finally, we will explore the co-occurrence of MetS, ED, and accelerated aging and its risk factors. As of September 2025, a total of 77 participants have already been included in cohort 2 and completed their clinic visit. Inclusion is estimated to continue until June 2026.

This study has several strengths, including the availability of a large representative national cohort of survivors of HSCT; the thoroughness of the collected data; and the clinical evaluation of components of MetS, ED, and accelerated aging in addition to self-reported outcomes assessed with validated questionnaires. To our knowledge, this is the first study to examine metabolic, vascular effects, and aging late effects together, as well as to analyze HSCT complications such as GvHD and ED syndromes as risk factors for these outcomes. Moreover, it is the first study to investigate potentially modifiable health behaviors in survivors of HSCT.

However, the extensiveness of data collection brings challenges in participant recruitment and achieving a complete dataset. Participating in the study requires a significant time investment from participants, and some may find the burden too great or may forget to complete certain study parts. To address this, we will regularly track the completeness of the data and discuss strategies to motivate participants to complete all required assessments.

In conclusion, this study will provide valuable insights into the prevalence of MetS, ED, and accelerated aging and their co-occurrence in survivors of HSCT in childhood for a hematological malignancy. Furthermore, it will also identify previously unexplored as well as potentially modifiable risk factors for these late sequelae. The gained knowledge will inform the optimization of surveillance guidelines for long-term follow-up care of these survivors. In addition, the findings will help to develop health behavioral and potentially anti-inflammatory interventions aimed at mitigating these severe late effects in survivors at risk, ultimately improving their quality of life. Through this knowledge, the MetVasA study aims to significantly improve the well-being of these people.

 Abbreviations 6MWT

6-minute-walking test

 CVD

cardiovascular disease

 DCCSS

Dutch Childhood Cancer Survivor Study

 DXA

dual-energy x-ray absorptiometry

 ED

endothelial dysfunction

 GvHD

graft-versus-host disease

 HSCT

hematopoietic stem cell transplantation

 MetS

metabolic syndrome

 MetVasA

Metabolic Syndrome, Vascular Damage, and Accelerated Aging

 RHI

reactive hyperemia index

 SRT

steep ramp test

 WC

waist circumference

The authors would like to thank all participating survivors of childhood cancer and their families for their contributions. The authors would like to further thank the other members of the Dutch Childhood Oncology Group LATER consortium (Eline van Dulmen-den Broeder, Marry van de Heuvel-Eibrink, Wim Tissing, Jacqueline Loonen, Cécile Ronckers, Andrica de Vries, Marloes Louwerens, Margriet van der Heiden-van der Loo, Sebastian Neggers, Hanneke van Santen), the PROM Core Facility, Anouk Remmits, Maria Boersma, Monique Hobbelink, Arthur Braat, Heleen Stam, all LATER physicians and nurse practitioners, outpatient clinic medical assistants, and data managers) for their contribution. The artificial intelligence tool ChatGPT was used to optimize readability of certain parts of the original manuscript. After using this tool, the authors carefully reviewed and edited the content as needed.

 Data Availability

The datasets generated during this study will be available from the corresponding author on reasonable request. The data are not publicly available due to privacy and ethical restrictions.

 Funding

This study is funded by the KiKa Foundation (grant 433).

Conceptualization: LCMK, SMFP, and DB; methodology: LJA, HJHvdP, MF, EAMF, MMWK, RRLvL, PvdT, JW, LCMK, SMFP, and DB; funding acquisition: LCMK, SMFP, and DB; investigation and project administration: LJA, SMFP, and DB; resources: HJHvdP, EAMF, LHG, RRLvL, PvdT, and SMFP; supervision: SMFP and DB; visualization: LJA, SMFP, and DB; writing – original draft: LJA, SMFP, and DB; writing – review & editing: LJA, SMFP, DB, HJHvdP, MF, EAMF, LHG, MMWK, RRLvL, PvdT, JW, and LCMK.

None declared.

 Passweg JR Baldomero H Ciceri F de la Cámara R Glass B Greco R Hazenberg MD Kalwak K McLornan DP Neven B Perić Z Risitano AM Ruggeri A Snowden JA Sureda A Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT Bone Marrow Transplant 2024 06 59 6 803 12 10.1038/s41409-024-02248-9 38438647 10.1038/s41409-024-02248-9 PMC11161408 Cusatis R Litovich C Feng Z Allbee-Johnson M Kapfhammer M Mattila D Akinola I Phelan R Broglie L Auletta JJ Steinert P Bolon YT Akhtar O Bloomquist J Chen M Devine SM Bupp C Hamadani M Hengen M Jaglowski S Kaur M Kuxhausen M Lee SJ Moskop A Page KM Pasquini MC Rizzo D Saber W Spellman SR Stefanski HE Tuschl E Yusuf R Zhan K Flynn KE Shaw BE Current trends and outcomes in cellular therapy activity in the United States, including prospective patient-reported outcomes data collection in the Center for International Blood and Marrow Transplant Research Registry Transplant Cell Ther 2024 09 30 9 917.e1 .e12 10.1016/j.jtct.2024.06.021 38944153 S2666-6367(24)00482-2 PMC11587342 Armenian SH Sun CL Kawashima T Arora M Leisenring W Sklar CA Baker KS Francisco L Teh JB Mills G Wong FL Rosenthal J Diller LR Hudson MM Oeffinger KC Forman SJ Robison LL Bhatia S Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS) Blood 2011 08 04 118 5 1413 20 10.1182/blood-2011-01-331835 21652685 S0006-4971(20)40836-5 PMC3152502 Chow EJ Anderson L Baker KS Bhatia S Guilcher GM Huang JT Pelletier W Perkins JL Rivard LS Schechter T Shah AJ Wilson KD Wong K Grewal SS Armenian SH Meacham LR Mulrooney DA Castellino SM Late effects surveillance recommendations among survivors of childhood hematopoietic cell transplantation: a Children's Oncology Group report Biol Blood Marrow Transplant 2016 05 22 5 782 95 10.1016/j.bbmt.2016.01.023 26802323 S1083-8791(16)00089-6 PMC4826622 Baker KS Bresters D Sande JE The burden of cure: long-term side effects following hematopoietic stem cell transplantation (HSCT) in children Pediatr Clin North Am 2010 02 57 1 323 42 10.1016/j.pcl.2009.11.008 20307723 S0031-3955(09)00171-0 Sun CL Francisco L Kawashima T Leisenring W Robison LL Baker KS Weisdorf DJ Forman SJ Bhatia S Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study Blood 2010 10 28 116 17 3129 39; quiz 3377 10.1182/blood-2009-06-229369 20656930 S0006-4971(20)31176-9 PMC2995350 Sun CL Kersey JH Francisco L Armenian SH Baker KS Weisdorf DJ Forman SJ Bhatia S Burden of morbidity in 10+ year survivors of hematopoietic cell transplantation: report from the bone marrow transplantation survivor study Biol Blood Marrow Transplant 2013 07 19 7 1073 80 10.1016/j.bbmt.2013.04.002 23583827 S1083-8791(13)00147-X PMC3691346 Bresters D van Gils IC Kollen W Ball LM Oostdijk W van der Bom JG Egeler RM High burden of late effects after haematopoietic stem cell transplantation in childhood: a single-centre study Bone Marrow Transplant 2010 01 45 1 79 85 10.1038/bmt.2009.92 19421172 bmt200992 Wilhelmsson M Vatanen A Borgström B Gustafsson B Taskinen M Saarinen-Pihkala UM Winiarski J Jahnukainen K Adverse health events and late mortality after pediatric allogeneic hematopoietic SCT-two decades of longitudinal follow-up Bone Marrow Transplant 2015 06 50 6 850 7 10.1038/bmt.2015.43 25798676 bmt201543 Vrooman LM Millard HR Brazauskas R Majhail NS Battiwalla M Flowers ME Savani BN Akpek G Aljurf M Bajwa R Baker KS Beitinjaneh A Bitan M Buchbinder D Chow E Dandoy C Dietz AC Diller L Gale RP Hashmi SK Hayashi RJ Hematti P Kamble RT Kasow KA Kletzel M Lazarus HM Malone AK Marks DI O'Brien TA Olsson RF Ringden O Seo S Steinberg A Yu LC Warwick A Shaw B Duncan C Survival and late effects after allogeneic hematopoietic cell transplantation for hematologic malignancy at less than three years of age Biol Blood Marrow Transplant 2017 08 23 8 1327 34 10.1016/j.bbmt.2017.04.017 28461213 S1083-8791(17)30426-3 PMC5666571 Leahey AM Teunissen H Friedman DL Moshang T Lange BJ Meadows AT Late effects of chemotherapy compared to bone marrow transplantation in the treatment of pediatric acute myeloid leukemia and myelodysplasia Med Pediatr Oncol 1999 03 32 3 163 9 10.1002/(sici)1096-911x(199903)32:3<163::aid-mpo1>3.0.co;2-# 10064182 10.1002/(SICI)1096-911X(199903)32:3<163::AID-MPO1>3.0.CO;2-# Ferry C Gemayel G Rocha V Labopin M Esperou H Robin M de Latour RP Ribaud P Devergie A Leblanc T Gluckman E Baruchel A Socié G Long-term outcomes after allogeneic stem cell transplantation for children with hematological malignancies Bone Marrow Transplant 2007 08 40 3 219 24 10.1038/sj.bmt.1705710 17530002 1705710 Baker KS Chow E Steinberger J Metabolic syndrome and cardiovascular risk in survivors after hematopoietic cell transplantation Bone Marrow Transplant 2012 05 47 5 619 25 10.1038/bmt.2011.118 21643022 bmt2011118 Bielorai B Weintraub Y Hutt D Hemi R Kanety H Modan-Moses D Goldstein G Hadar D Lerner-Geva L Toren A Pinhas-Hamiel O The metabolic syndrome and its components in pediatric survivors of allogeneic hematopoietic stem cell transplantation Clin Transplant 2017 03 31 3 10.1111/ctr.12903 28039914 Bizzarri C Pinto RM Ciccone S Brescia LP Locatelli F Cappa M Early and progressive insulin resistance in young, non-obese cancer survivors treated with hematopoietic stem cell transplantation Pediatr Blood Cancer 2015 09 62 9 1650 5 10.1002/pbc.25603 26017459 Chow EJ Simmons JH Roth CL Baker KS Hoffmeister PA Sanders JE Friedman DL Increased cardiometabolic traits in pediatric survivors of acute lymphoblastic leukemia treated with total body irradiation Biol Blood Marrow Transplant 2010 12 16 12 1674 81 10.1016/j.bbmt.2010.05.016 20685399 S1083-8791(10)00229-6 PMC2975816 Frisk P Rössner SM Norgren S Arvidson J Gustafsson J Glucose metabolism and body composition in young adults treated with TBI during childhood Bone Marrow Transplant 2011 10 46 10 1303 8 10.1038/bmt.2010.307 21151187 bmt2010307 Hoffmeister PA Storer BE Sanders JE Diabetes mellitus in long-term survivors of pediatric hematopoietic cell transplantation J Pediatr Hematol Oncol 2004 02 26 2 81 90 10.1097/00043426-200402000-00003 14767193 00043426-200402000-00003 Inaba H Yang J Kaste SC Hartford CM Motosue MS Chemaitilly W Triplett BM Shook DR Pui CH Leung W Longitudinal changes in body mass and composition in survivors of childhood hematologic malignancies after allogeneic hematopoietic stem-cell transplantation J Clin Oncol 2012 11 10 30 32 3991 7 10.1200/JCO.2011.40.0457 23032628 JCO.2011.40.0457 PMC3675688 Majhail NS Flowers ME Ness KK Jagasia M Carpenter PA Arora M Arai S Johnston L Martin PJ Baker KS Lee SJ Burns LJ High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation Bone Marrow Transplant 2009 01 43 1 49 54 10.1038/bmt.2008.263 18724397 bmt2008263 PMC2628412 Duncan CN Brazauskas R Huang J Shaw BE Majhail NS Savani BN Flowers ME Battiwalla M Beebe K Dietz AC Dvorak CC Giller R Jacobsohn DA Kletzel M Martin PL Nemecek ER Nuechterlein B Talano JA Pulsipher MA Baker KS Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation Bone Marrow Transplant 2018 10 53 10 1278 87 10.1038/s41409-018-0155-z 29581480 10.1038/s41409-018-0155-z PMC6158112 Oudin C Auquier P Bertrand Y Contet A Kanold J Sirvent N Thouvenin S Tabone MD Lutz P Ducassou S Plantaz D Dalle JH Gandemer V Beliard S Berbis J Vercasson C Barlogis V Baruchel A Leverger G Michel G Metabolic syndrome in adults who received hematopoietic stem cell transplantation for acute childhood leukemia: an LEA study Bone Marrow Transplant 2015 11 50 11 1438 44 10.1038/bmt.2015.167 26191949 bmt2015167 Wei C Thyagiarajan MS Hunt LP Shield JP Stevens MC Crowne EC Reduced insulin sensitivity in childhood survivors of haematopoietic stem cell transplantation is associated with lipodystropic and sarcopenic phenotypes Pediatr Blood Cancer 2015 11 62 11 1992 9 10.1002/pbc.25601 25989749 Bolier M de Winter DT Pluimakers VG Fiocco M van den Berg SA Bresters D van Dulmen-den Broeder E van der Heiden-van der Loo M Höfer I Janssens GO Kremer LC Loonen JL Louwerens M van der Pal HJ Pluijm SM Tissing WJ van Santen HM de Vries AC van der Lely AJ van den Heuvel-Eibrink MM Neggers SJ Prevalence and determinants of metabolic syndrome in 2338 childhood cancer survivors: a Dutch Childhood Cancer Survivor LATER 2 study Cancer 2025 01 01 131 1 e35681 10.1002/cncr.35681 39748458 PMC11695793 Metabool syndroom, naar leeftijd en geslacht Rijksinstituut voor Volksgezondheid en Milieu 2012 1 26 2025-09-01 https://www.rivm.nl/metabool-syndroom-naar-leeftijd-en-geslacht Pluimakers VG van Waas M Neggers SJ van den Heuvel-Eibrink MM Metabolic syndrome as cardiovascular risk factor in childhood cancer survivors Crit Rev Oncol Hematol 2019 01 133 129 41 10.1016/j.critrevonc.2018.10.010 30661649 S1040-8428(18)30204-X Fowkes FG Aboyans V Fowkes FJ McDermott MM Sampson UK Criqui MH Peripheral artery disease: epidemiology and global perspectives Nat Rev Cardiol 2017 03 14 3 156 70 10.1038/nrcardio.2016.179 27853158 nrcardio.2016.179 Borchert-Mörlins B Memaran N Sauer M Maecker-Kolhoff B Sykora KW Blöte R Bauer E Schmidt BM Melk A Beier R Cardiovascular risk factors and subclinical organ damage after hematopoietic stem cell transplantation in pediatric age Bone Marrow Transplant 2018 08 53 8 983 92 10.1038/s41409-018-0104-x 29426831 10.1038/s41409-018-0104-x Vasbinder A Hoeger CW Catalan T Anderson E Chu C Kotzin M Xie J Kaakati R Berlin HP Shadid H Perry D Pan M Takiar R Padalia K Mills J Meloche C Bardwell A Rochlen M Blakely P Leja M Banerjee M Riwes M Magenau J Anand S Ghosh M Pawarode A Yanik G Nathan S Maciejewski J Okwuosa T Hayek SS Cardiovascular events after hematopoietic stem cell transplant: incidence and risk factors JACC CardioOncol 2023 09 19 5 6 821 32 10.1016/j.jaccao.2023.07.007 38205002 S2666-0873(23)00239-9 PMC10774793 Rotz SJ Ryan TD Hayek SS Cardiovascular disease and its management in children and adults undergoing hematopoietic stem cell transplantation J Thromb Thrombolysis 2021 05 51 4 854 69 10.1007/s11239-020-02344-9 33230704 10.1007/s11239-020-02344-9 PMC8085022 Tichelli A Passweg J Wójcik D Rovó A Harousseau JL Masszi T Zander A Békássy A Crawley C Arat M Sica S Lutz P Socié G Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the late effects working party of the European Group for Blood and Marrow Transplantation Haematologica 2008 08 93 8 1203 10 10.3324/haematol.12949 18556401 haematol.12949 Crocco M d'Annunzio G La Valle A Piccolo G Chiarenza DS Bigatti C Molteni M Milanaccio C Garrè ML Di Iorgi N Maghnie M Endothelial dysfunction in childhood cancer survivors: a narrative review Life (Basel) 2021 12 29 12 1 45 10.3390/life12010045 35054438 life12010045 PMC8780257 Gusev E Sarapultsev A Atherosclerosis and inflammation: insights from the theory of general pathological processes Int J Mol Sci 2023 04 26 24 9 7910 10.3390/ijms24097910 37175617 ijms24097910 PMC10178362 Eissa HM Lu L Baassiri M Bhakta N Ehrhardt MJ Triplett BM Green DM Mulrooney DA Robison LL Hudson MM Ness KK Chronic disease burden and frailty in survivors of childhood HSCT: a report from the St. Jude Lifetime Cohort Study Blood Adv 2017 11 07 1 24 2243 6 10.1182/bloodadvances.2017010280 29296872 2017/010280 PMC5737129 Ness KK Armstrong GT Kundu M Wilson CL Tchkonia T Kirkland JL Frailty in childhood cancer survivors Cancer 2015 05 15 121 10 1540 7 10.1002/cncr.29211 25529481 PMC4424063 Armenian SH Gibson CJ Rockne RC Ness KK Premature aging in young cancer survivors J Natl Cancer Inst 2019 03 01 111 3 226 32 10.1093/jnci/djy229 30715446 5305760 Arora M Chen Y Wu J Hageman L Ness E Kung M Francisco L Bosworth A Weisdorf DJ Forman SJ Landier W Pamukçuoğlu M Armenian SH Wong FL Bhatia S Longitudinal trajectory of frailty in blood or marrow transplant survivors: report from the Blood or Marrow Transplant Survivor Study Cancer 2021 03 01 127 5 794 800 10.1002/cncr.33313 33206383 PMC8833138 Pluijm SM Accelerated aging as a paradigm to understand the late effects of cancer therapies Front Horm Res 2021 54 16 24 10.1159/000518816 34569544 000518816 Kim JA Montagnani M Koh KK Quon MJ Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms Circulation 2006 04 18 113 15 1888 904 10.1161/CIRCULATIONAHA.105.563213 16618833 113/15/1888 Carreras E Barcelona Endothelium Team (BET) Vascular endothelial syndromes after HCT: 2020 update Bone Marrow Transplant 2020 10 55 10 1885 7 10.1038/s41409-020-0852-2 32203255 10.1038/s41409-020-0852-2 Hildebrandt GC Chao N Endothelial cell function and endothelial-related disorders following haematopoietic cell transplantation Br J Haematol 2020 08 190 4 508 19 10.1111/bjh.16621 32319084 PMC7496350 Pagliuca S Michonneau D Sicre de Fontbrune F Sutra Del Galy A Xhaard A Robin M Peffault de Latour R Socie G Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions Blood Adv 2019 08 13 3 15 2424 35 10.1182/bloodadvances.2019000143 31409584 bloodadvances.2019000143 PMC6693000 Armenian SH Chemaitilly W Chen M Chow EJ Duncan CN Jones LW Pulsipher MA Remaley AT Rovo A Salooja N Battiwalla M National Institutes of Health hematopoietic cell transplantation late effects initiative: the cardiovascular disease and associated risk factors working group report Biol Blood Marrow Transplant 2017 02 23 2 201 10 10.1016/j.bbmt.2016.08.019 27590105 S1083-8791(16)30294-4 PMC5526451 Hill GR Koyama M Cytokines and costimulation in acute graft-versus-host disease Blood 2020 07 23 136 4 418 28 10.1182/blood.2019000952 32526028 S0006-4971(20)61861-4 PMC7378458 Felicetti F Cento AS Fornengo P Cassader M Mastrocola R D'Ascenzo F Settanni F Benso A Arvat E Collino M Fagioli F Aragno M Brignardello E Advanced glycation end products and chronic inflammation in adult survivors of childhood leukemia treated with hematopoietic stem cell transplantation Pediatr Blood Cancer 2020 03 67 3 e28106 10.1002/pbc.28106 31820553 Cooke KR Luznik L Sarantopoulos S Hakim FT Jagasia M Fowler DH van den Brink MR Hansen JA Parkman R Miklos DB Martin PJ Paczesny S Vogelsang G Pavletic S Ritz J Schultz KR Blazar BR The biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease Biol Blood Marrow Transplant 2017 02 23 2 211 34 10.1016/j.bbmt.2016.09.023 27713092 S1083-8791(16)30386-X PMC6020045 Inagaki J Moritake H Nishikawa T Hyakuna N Okada M Suenobu SI Nagai K Honda Y Shimomura M Fukano R Noguchi M Kurauchi K Tanioka S Okamura J Long-term morbidity and mortality in children with chronic graft-versus-host disease classified by National Institutes of Health consensus criteria after allogeneic hematopoietic stem cell transplantation Biol Blood Marrow Transplant 2015 11 21 11 1973 80 10.1016/j.bbmt.2015.07.025 26234723 S1083-8791(15)00502-9 Jagasia MH Greinix HT Arora M Williams KM Wolff D Cowen EW Palmer J Weisdorf D Treister NS Cheng GS Kerr H Stratton P Duarte RF McDonald GB Inamoto Y Vigorito A Arai S Datiles MB Jacobsohn D Heller T Kitko CL Mitchell SA Martin PJ Shulman H Wu RS Cutler CS Vogelsang GB Lee SJ Pavletic SZ Flowers ME National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report Biol Blood Marrow Transplant 2015 03 21 3 389 401.e1 10.1016/j.bbmt.2014.12.001 25529383 S1083-8791(14)01378-0 PMC4329079 MacDonald KP Hill GR Blazar BR Chronic graft-versus-host disease: biological insights from preclinical and clinical studies Blood 2017 01 05 129 1 13 21 10.1182/blood-2016-06-686618 27821504 S0006-4971(20)33821-0 PMC5216261 Nieder ML McDonald GB Kida A Hingorani S Armenian SH Cooke KR Pulsipher MA Baker KS National Cancer Institute-National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: long-term organ damage and dysfunction Biol Blood Marrow Transplant 2011 11 17 11 1573 84 10.1016/j.bbmt.2011.09.013 21963877 S1083-8791(11)00389-2 PMC3215762 Socié G Salooja N Cohen A Rovelli A Carreras E Locasciulli A Korthof E Weis J Levy V Tichelli A Nonmalignant late effects after allogeneic stem cell transplantation Blood 2003 05 01 101 9 3373 85 10.1182/blood-2002-07-2231 12511420 S0006-4971(20)50712-X Slater ME Steinberger J Ross JA Kelly AS Chow EJ Koves IH Hoffmeister P Sinaiko AR Petryk A Moran A Lee J Chow LS Baker KS Physical activity, fitness, and cardiometabolic risk factors in adult survivors of childhood cancer with a history of hematopoietic cell transplantation Biol Blood Marrow Transplant 2015 07 21 7 1278 83 10.1016/j.bbmt.2015.04.007 25865649 S1083-8791(15)00251-7 PMC4466057 Bovolini A Garcia J Andrade MA Duarte JA Metabolic syndrome pathophysiology and predisposing factors Int J Sports Med 2021 03 42 3 199 214 10.1055/a-1263-0898 33075830 Gallardo-Alfaro L Bibiloni MD Mascaró CM Montemayor S Ruiz-Canela M Salas-Salvadó J Corella D Fitó M Romaguera D Vioque J Alonso-Gómez ÁM Wärnberg J Martínez JA Serra-Majem L Estruch R Fernández-García JC Lapetra J Pintó X García Ríos A Bueno-Cavanillas A Gaforio JJ Matía-Martín P Daimiel L Micó-Pérez RM Vidal J Vázquez C Ros E Fernandez-Lázaro CI Becerra-Tomás N Gimenez-Alba IM Zomeño MD Konieczna J Compañ-Gabucio L Tojal-Sierra L Pérez-López J Zulet MÁ Casañas-Quintana T Castro-Barquero S Gómez-Pérez AM Santos-Lozano JM Galera A Basterra-Gortari FJ Basora J Saiz C Pérez-Vega KA Galmés-Panadés AM Tercero-Maciá C Sorto-Sánchez C Sayón-Orea C García-Gavilán J Muñoz-Martínez J Tur JA Leisure-time physical activity, sedentary behaviour and diet quality are associated with metabolic syndrome severity: the PREDIMED-Plus study Nutrients 2020 04 07 12 4 1013 10.3390/nu12041013 32272653 nu12041013 PMC7230557 Lechner K von Schacky C McKenzie AL Worm N Nixdorff U Lechner B Kränkel N Halle M Krauss RM Scherr J Lifestyle factors and high-risk atherosclerosis: pathways and mechanisms beyond traditional risk factors Eur J Prev Cardiol 2020 03 13 27 4 394 406 10.1177/2047487319869400 31408370 PMC7065445 Friedman SM Lifestyle (medicine) and healthy aging Clin Geriatr Med 2020 11 36 4 645 53 10.1016/j.cger.2020.06.007 33010900 S0749-0690(20)30049-5 Lee C Kim S Tecca H Bo-Subait S Phelan R Brazauskas R Buchbinder D Hamilton BK Battiwalla M Majhail NS Lazarus HM Shaw PJ Marks DI Litzow MR Chhabra S Inamoto Y DeFilipp Z Hildebrandt GC Olsson RF Kasow KA Liesveld JL Rotz SJ Badawy SM Bhatt NS Yared JA Page KM Arellano ML Kent M Farhadfar N Seo S Hematti P Freytes CO Rovó A Ganguly S Nathan S Burns L Shaw BE Muffly LS Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia Blood Adv 2020 03 24 4 6 983 92 10.1182/bloodadvances.2019001126 32168378 S2473-9529(20)31418-X PMC7094022 Gerbek T Thomsen BL Muhic E Christiansen T Sørensen K Ifversen M Kofoed K Müller K Metabolic syndrome as a late effect of childhood hematopoietic stem cell transplantation - a thorough statistical evaluation of putative risk factors Pediatr Transplant 2023 06 17 27 4 e14530 10.1111/petr.14530 37069730 Ness KK Kirkland JL Gramatges MM Wang Z Kundu M McCastlain K Li-Harms X Zhang J Tchkonia T Pluijm SM Armstrong GT Premature physiologic aging as a paradigm for understanding increased risk of adverse health across the lifespan of survivors of childhood cancer J Clin Oncol 2018 07 20 36 21 2206 15 10.1200/JCO.2017.76.7467 29874132 PMC6553838 Smitherman AB Wood WA Mitin N Ayer Miller VL Deal AM Davis IJ Blatt J Gold SH Muss HB Accelerated aging among childhood, adolescent, and young adult cancer survivors is evidenced by increased expression of p16INK4a and frailty Cancer 2020 11 15 126 22 4975 83 10.1002/cncr.33112 32830315 PMC7607511 Feijen EA Teepen JC van Dulmen-den Broeder E van den Heuvel-Eibrink MM van der Heiden-van der Loo M van der Pal HJ de Vries AC Louwerens M Bresters D Versluys B de Ridder H Veening M van Leeuwen FE Grootenhuis M Maurice-Stam H van Santen HM Neggers SJ Pluijm S den Hartogh J Ronckers CM Tissing WJ Loonen JJ Kremer LC Clinical evaluation of late outcomes in Dutch childhood cancer survivors: methodology of the DCCSS LATER 2 study Pediatr Blood Cancer 2023 05 70 5 e30212 10.1002/pbc.30212 36651687 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) JAMA 2001 05 16 285 19 2486 97 10.1001/jama.285.19.2486 11368702 jsc10094 Ahrens W Moreno LA Mårild S Molnár D Siani A De Henauw S Böhmann J Günther K Hadjigeorgiou C Iacoviello L Lissner L Veidebaum T Pohlabeln H Pigeot I Metabolic syndrome in young children: definitions and results of the IDEFICS study Int J Obes (Lond) 2014 09 38 Suppl 2 S4 14 10.1038/ijo.2014.130 25376220 ijo2014130 Tropeano A Corica D Li Pomi A Pepe G Morabito LA Curatola SL Casto C Aversa T Wasniewska M The metabolic syndrome in pediatrics: do we have a reliable definition? A systematic review Eur J Endocrinol 2021 07 01 185 2 265 78 10.1530/EJE-21-0238 34061767 EJE-21-0238 van den Oever SR Mulder RL Oeffinger KC Gietema JA Skinner R Constine LS Wallace WH Armenian S Barnea D Bardi E Belle FN Brown AL Chemaitilly W Crowne L van Dalen EC Denzer C Ehrhardt MJ Felicetti F Friedman DN Fulbright J Glaser AW Giwercman A Sangstuen Haugnes H Hayek S Hennewig U van den Heuvel-Eibrink MM Haupt R van Iersel L Kamdar K Lefrandt J Levitt G Morsellino V Mulrooney DA Murray RD Neggers S Ness KK Neville KA Nock NL Otth M Prasad PK van Santen HM Schindera C Rath SR Steinberger J Terenziani M Varedi M Walwyn T Wei C Hudson MM Kremer LC Nuver J Tonorezos E Metabolic syndrome in childhood, adolescent, and young adult cancer survivors: recommendations for surveillance from the International Late Effects of Childhood Cancer Guideline Harmonization Group Eur J Endocrinol 2025 03 27 192 4 S27 40 10.1093/ejendo/lvaf046 40103414 8086479 Axtell AL Gomari FA Cooke JP Assessing endothelial vasodilator function with the Endo-PAT 2000 J Vis Exp 2010 10 15 44 2167 10.3791/2167 20972417 2167 PMC3143035 Hudgins LC Annavajjhala V Kovanlikaya A Frank MD Solomon A Parker TS Cooper RS Non-invasive assessment of endothelial function in children with obesity and lipid disorders Cardiol Young 2016 03 26 3 532 8 10.1017/S1047951115000657 25939357 S1047951115000657 PMC5157163 Groner JA Joshi M Bauer JA Pediatric precursors of adult cardiovascular disease: noninvasive assessment of early vascular changes in children and adolescents Pediatrics 2006 10 118 4 1683 91 10.1542/peds.2005-2992 17015562 118/4/1683 Rubinshtein R Kuvin JT Soffler M Lennon RJ Lavi S Nelson RE Pumper GM Lerman LO Lerman A Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events Eur Heart J 2010 05 24 31 9 1142 8 10.1093/eurheartj/ehq010 20181680 ehq010 Gordijn MS Cremers EM Kaspers GJ Gemke RJ Fatigue in children: reliability and validity of the Dutch PedsQL™ Multidimensional Fatigue Scale Qual Life Res 2011 09 19 20 7 1103 8 10.1007/s11136-010-9836-9 21246290 PMC3161196 Vasold KL Parks AC Phelan DM Pontifex MB Pivarnik JM Reliability and validity of commercially available low-cost bioelectrical impedance analysis Int J Sport Nutr Exerc Metab 2019 07 01 29 4 406 10 10.1123/ijsnem.2018-0283 30507268 Sisay BG Jima BR Habtamu M Gebru NW Hassen HY Predictive ability of anthropometric indices in identifying metabolic syndrome among US adolescents 10 to 19 years old: analysis from the National Health and Nutrition Examination Survey 2011 to 2018 data set Nutrition 2023 09 113 112081 10.1016/j.nut.2023.112081 37321045 S0899-9007(23)00110-7 Cazzoletti L Zanolin ME Dorelli G Ferrari P Dalle Carbonare LG Crisafulli E Alemayohu MA Olivieri M Verlato G Ferrari M Six-minute walk distance in healthy subjects: reference standards from a general population sample Respir Res 2022 04 05 23 1 83 10.1186/s12931-022-02003-y 35382813 10.1186/s12931-022-02003-y PMC8985335 Soubra R Chkeir A Novella JL A systematic review of thirty-one assessment tests to evaluate mobility in older adults Biomed Res Int 2019 06 20 2019 1354362 10.1155/2019/1354362 31321227 PMC6610744 Solway S Brooks D Lacasse Y Thomas S A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain Chest 2001 01 119 1 256 70 10.1378/chest.119.1.256 11157613 S0012-3692(15)37593-0 Ware JE Jr Sherbourne CD The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection Med Care 1992 06 30 6 473 83 1593914 Gobbens RJ van Assen MA Luijkx KG Wijnen-Sponselee MT Schols JM The Tilburg Frailty Indicator: psychometric properties J Am Med Dir Assoc 2010 06 11 5 344 55 10.1016/j.jamda.2009.11.003 20511102 S1525-8610(09)00406-X Tomkinson GR Carver KD Atkinson F Daniell ND Lewis LK Fitzgerald JS Lang JJ Ortega FB European normative values for physical fitness in children and adolescents aged 9-17 years: results from 2 779 165 Eurofit performances representing 30 countries Br J Sports Med 2018 11 52 22 1445 56 10.1136/bjsports-2017-098253 29191931 bjsports-2017-098253 Bergland AB Strand BH Norwegian reference values for the Short Physical Performance Battery (SPPB): the Tromsø Study BMC Geriatr 2019 08 08 19 1 216 10.1186/s12877-019-1234-8 31395008 10.1186/s12877-019-1234-8 PMC6686475 Dodds RM Syddall HE Cooper R Benzeval M Deary IJ Dennison EM Der G Gale CR Inskip HM Jagger C Kirkwood TB Lawlor DA Robinson SM Starr JM Steptoe A Tilling K Kuh D Cooper C Sayer AA Grip strength across the life course: normative data from twelve British studies PLoS One 2014 9 12 e113637 10.1371/journal.pone.0113637 25474696 PONE-D-14-38921 PMC4256164 De Backer IC Schep G Hoogeveen A Vreugdenhil G Kester AD van Breda E Exercise testing and training in a cancer rehabilitation program: the advantage of the steep ramp test Arch Phys Med Rehabil 2007 05 88 5 610 6 10.1016/j.apmr.2007.02.013 17466730 S0003-9993(07)00111-6 Weemaes AT Beelen M Bongers BC Weijenberg MP Lenssen AF Criterion validity and responsiveness of the steep ramp test to evaluate aerobic capacity in survivors of cancer participating in a supervised exercise rehabilitation program Arch Phys Med Rehabil 2021 11 102 11 2150 6 10.1016/j.apmr.2021.04.016 34023324 S0003-9993(21)00375-0 Werkman MS Bongers BC Blatter T Takken T Wittink H Extended steep ramp test normative values for 19-24-year-old healthy active young adults Eur J Appl Physiol 2020 01 08 120 1 107 15 10.1007/s00421-019-04255-x 31705276 10.1007/s00421-019-04255-x PMC6969871 Wendel-Vos GC Schuit AJ Saris WH Kromhout D Reproducibility and relative validity of the short questionnaire to assess health-enhancing physical activity J Clin Epidemiol 2003 12 56 12 1163 9 10.1016/s0895-4356(03)00220-8 14680666 S0895435603002208 Yu L Buysse DJ Germain A Moul DE Stover A Dodds NE Johnston KL Pilkonis PA Development of short forms from the PROMIS™ sleep disturbance and Sleep-Related Impairment item banks Behav Sleep Med 2011 12 28 10 1 6 24 10.1080/15402002.2012.636266 22250775 PMC3261577 Terwee CB Roorda LD de Vet HC Dekker J Westhovens R van Leeuwen J Cella D Correia H Arnold B Perez B Boers M Dutch-Flemish translation of 17 item banks from the patient-reported outcomes measurement information system (PROMIS) Qual Life Res 2014 08 23 6 1733 41 10.1007/s11136-013-0611-6 24402179 Migueles JH Cadenas-Sanchez C Ekelund U Delisle Nyström C Mora-Gonzalez J Löf M Labayen I Ruiz JR Ortega FB Accelerometer data collection and processing criteria to assess physical activity and other outcomes: a systematic review and practical considerations Sports Med 2017 09 47 9 1821 45 10.1007/s40279-017-0716-0 28303543 10.1007/s40279-017-0716-0 PMC6231536 Kromhout D Spaaij CJ de Goede J Weggemans RM The 2015 Dutch food-based dietary guidelines Eur J Clin Nutr 2016 08 70 8 869 78 10.1038/ejcn.2016.52 27049034 ejcn201652 PMC5399142 Looman M Feskens EJ de Rijk M Meijboom S Biesbroek S Temme EH de Vries J Geelen A Development and evaluation of the Dutch Healthy Diet index 2015 Public Health Nutr 2017 09 20 13 2289 99 10.1017/S136898001700091X 28625202 S136898001700091X PMC10261559